IXICO's AGM Statement

January 29, 2016
News

Download full press release

29 January 2016, IXICO plc (Ticker: IXI) (‘IXICO’ or the ‘Company’), the brain health company, will hold its Annual General Meeting at 9.30am today at FTI Consulting, 200 Aldersgate, London EC1A 4HD.

At the meeting Dr Andrew Richards, the Company’s Chairman will make the following statement:

“I am pleased to report a strong performance in the year ended 30 September 2015 and that this momentum has continued into the current year. 

The delivery of existing contracted revenues together with our recently announced contracts in Alzheimer’s disease and Huntington’s disease remain an important part of our operational focus and investment.  Our relationships with these pharmaceutical customers allow us to demonstrate the value of our portfolio of digital products and data solutions.  Our agreement to develop and pilot Assessa® in the clinical management of Multiple Sclerosis with a pharmaceutical partner is a recent example of progress in executing this strategy.  The pilot deployment and planning the subsequent roll out will be a key focus for this coming year. 

We are continuing to showcase our digital healthcare products through pilots and partnerships with the NHS and 3rd sector organisations as a way of building our evidence base and profile.  The Optimal Medicine products, team, customers and US base are now part of the enlarged group, adding breadth to our brain health capabilities in real world data collection and clinical decision support.”

The Company further announces that Charles Spicer has stepped down as an Executive Director with immediate effect and will remain on the Board as a Non-Executive Director.

Charles has been involved with IXICO since 2011, first as an adviser on corporate strategy and subsequently joined the Board in July 2013.  He played a key role in the reverse takeover of Phytopharm plc in October 2013 and more recently, the acquisition of Optimal Medicine Limited.  Charles’ experience as a director and adviser in the medtech and life sciences sectors has been particularly invaluable as IXICO transitioned from a private company to a plc.  In his role as a Non-Executive Director he will continue to support the Company’s corporate development plans.

Dr Andrew Richards added: 

“I would like thank Charles for his support over the past five years.  He has played a pivotal role in developing IXICO’s corporate profile and we appreciate the advice and expertise that he has provided.  We are delighted that Charles will remain with the Company and continue to provide guidance in his ongoing Non-Executive role as we grow the business.”

 


 
Enquiries:
 
IXICO plc    
Derek Hill, CEO    
Susan Lowther, CFO    
Charles Spicer, VP Corporate Development    

+44 20 3763 7499
    
Peel Hunt LLP (Nominated Adviser and Broker)   
James Steel / Oliver Jackson    

 +44 20 7418 8900


Daniel Stewart & Company (Joint Broker)    
Martin Lampshire / David Coffman    

+44 207 776 6550

FTI Consulting Limited (Investor Relations)    
Simon Conway / Mo Noonan / Matthew Moss    

+44 20 3727 1000


Notes to Editors

About IXICO
IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com.